📢 DDReg Knowledge Capsule – Episode [11]while the COVID-19 pandemic accelerated mRNA visibility, its scope now includes cancer immunotherapies, treatments for genetic and metabolic disorders, and regenerative medicine, with the global market projected for significant growth. The text also outlines both the key benefits of mRNA, such as speed and versatility, and the inherent challenges, including stability issues, delivery complexity, and high manufacturing costs. Finally, the document details the regulatory landscape for mRNA therapeutics, highlighting frameworks from the U.S. FDA, the EMA, and the WHO, and asserts DDReg’s role in helping companies navigate these complex approval pathways.

The United Arab Emirates is one of the Middle East's fastest-growing pharmaceutical markets, offering a strategic gateway for global manufacturers But entering this lucrative market requires navigating a complex regulatory landscape.In this episode, we unpack the essential guidelines for the drug product registration process in UAE. We explore the roles of the two key regulatory authorities: the Ministry of Health and Prevention (MOHAP), which handles facility licensing and product importation, and the Emirates Drug Establishment (EDE), which oversees everything from clinical testing to drug approvals.

📢 DDReg Knowledge Capsule – Episode [9]Overview of pharmacovigilance in New Zealand, highlighting the regulatory framework overseen by Medsafe under the Medicines Act 1981. It explains that the country participates in the WHO International Drug Monitoring Programme and uses systems like the Suspected Medicine Adverse Reaction Search (SMARS) database to gather post-market safety information. The text outlines the responsibilities of pharmaceutical sponsors, including appointing a contact person and adhering to strict timelines—such as reporting serious adverse reactions within 15 days and urgent safety issues within 72 hours—as mandated by updated guidelines.

📢 DDReg Knowledge Capsule – Episode [9]pharmacovigilance (PV) inspections preparedness, conducted globally by regulatory bodies to ensure compliance among marketing authorization holders. These inspections, which can be announced or unannounced, verify that systems, facilities, and processes adhere to PV requirements and aim to identify non-compliance that could potentially harm patients. The article outlines various types of PV inspections, common areas covered, and the specific agendas of key regulatory authorities, including the FDA, EMA, and MHRA.

📢 DDReg Knowledge Capsule – Episode [8]In-depth guide to the drug registration process in Mexico, highlighting its importance as the second-largest pharmaceutical market in Latin America. The core of the process is overseen by the Federal Commission for the Protection against Sanitary Risks (COFEPRIS), which categorises medicines into distinct regulatory pathways, such as New Chemical Entities and generics, each with different timelines and requirements. Key strategic elements for successful market entry include submitting all required documents in Spanish, appointing a mandatory local legal representative ("responsable sanitario"), and adhering to Good Manufacturing Practice (GMP) standards.

📢 DDReg Knowledge Capsule – Episode [8]In this podcast, we cover the steps and points that any global and local entity should follow when planning to register their new drug product in the Indian market.

📢 DDReg Knowledge Capsule – Episode [7]⁠⁠⁠ In-depth analysis of the European Union’s Packaging and Packaging Waste Regulation (EU PPWR), officially designated as Regulation (EU) 2024/1781, which replaces a previous directive to mandate stricter sustainability standards across the EU. This new regulation, which entered into force in February 2025, aims to prevent waste, ensure all packaging is recyclable by 2030, and harmonize rules across member states. A significant portion of the text focuses on how the PPWR specifically impacts the pharmaceutical industry, noting that while contact-sensitive medicinal packaging receives temporary exemptions from recycled content and immediate recyclability targets due to safety concerns, outer and secondary packaging must comply with rules concerning recyclability and maximum empty space.

📢 DDReg Knowledge Capsule – Episode [6]⁠Introduces the concept of Translational Biology and explains how this field is accelerating the development of new therapies by creating a continuous feedback loop between laboratory discovery and patient care. The article outlines the multi-stage Translational Biology Pipeline (T0 to T4), which moves findings from basic research through clinical trials and into public health practice. It also identifies several cutting-edge tools and techniques used in this research, such as proteomics, biomarker analysis, and computational modeling, alongside the primary challenges related to funding and regulatory complexity.

📢 DDReg Knowledge Capsule – Episode [6]Strategic Pharmacovigilance Checklist for Biosimilar Safety in 2025," which offers guidance on managing the increasing complexities of biosimilar safety. The article explains that the biosimilar market is rapidly expanding, necessitating robust pharmacovigilance (PV) to ensure patient safety and mitigate risks. It presents a comprehensive checklist covering key areas such as creating unique Risk Management Plans (RMPs), prioritizing immunogenicity oversight, ensuring detailed traceability and product identification, and employing advanced signal detection techniques using AI/ML tools.

📢 DDReg Knowledge Capsule – Episode [5]Overview of the drug approval process in the Chinese pharmaceutical market, highlighting its significance as the world's second-largest. It details the types of drugs approved, including innovative medicines, generics, and traditional Chinese medicines, and identifies the key regulatory bodies, namely the National Medical Products Administration (NMPA) and the Center for Drug Evaluation (CDE). https://resource.ddregpharma.com/blogs/drug-approval-process-in-china-market/